SeaSci Pharmaceuticals: Completion of the first batch of participants in the HP515 Phase II clinical trial.

H-Choice Pharmaceutical announced that the Phase II clinical trial of HP515, a drug developed independently by the company for the treatment of metabolic associated fatty liver disease, has completed enrollment of the first batch of participants. HP515 is an orally administered highly selective THR- agonist developed by the company, which can directly act on THR- to activate downstream gene transcription, enhance liver cell lipid metabolism activity, improve liver fat metabolism, and reduce lipotoxicity to achieve improvement in metabolic associated fatty liver disease.